A variant of combined treatment for chronic central serous chorioretinopathy complicated by type 1 choroidal neovascularization

A. V. Tereshchenko, E. Erokhina, Y. Sidorova, I. Trifanenkova
{"title":"A variant of combined treatment for chronic central serous chorioretinopathy complicated by type 1 choroidal neovascularization","authors":"A. V. Tereshchenko, E. Erokhina, Y. Sidorova, I. Trifanenkova","doi":"10.21516/2072-0076-2023-16-1-82-89","DOIUrl":null,"url":null,"abstract":"Purpose: to evaluate the effectiveness of combined treatment of chronic central serous chorioretinopathy (CSCRP) complicated by type 1 choroidal neovascularization (CNV) by subthreshold micropulse laser exposure (SMILE) and intravitreal injection of angiogenesis inhibitors ( IIAI). Material and methods. 37 patients (20 men and 17 women) with monolateral chronic recurrent CSCRP complicated by type 1 CNV, aged 35 to 57 (ave. 43.6 ± 6.7 yrs.) at the moment of first referral, were divided into two groups. The retrospective group included 15 patients (15 eyes) whose first phase of treatment consisted in IIAI (up to 5 injections with an interval of one month). Those who showed no treatment effect were given a SMILE procedure one day before the 6th injection. If neurosensory retinal detachment persisted, the combined treatment (SMILE + IIAI) was repeated monthly until the neurosensory retina could be fully attached, whereupon the patients were transferred to monotherapy with anti-VEGF injections, gradually increasing the interval between the injections. The main group included 22 patients (22 eyes), whose treatment began with a single IIAI. If no neurosensory retinal detachment resorption occurred, the patients received a SMILE procedure one day before the second IIAI injection. The combined treatment was repeated monthly until neurosensory retinal detachment completely resorbed, then the treatment continued with IIAI alone with a gradual increase of intervals between the injections. Results. The number of IIAI in the main group (5 to 8, ave. 6.1 ± 0.8) was significantly lower than in the retrospective group (8 to 10, ave. 8.8 ± 0.77). Best corrected visual acuity increased in both groups, but the main group showed a better central photosensitivity, which is associated with the faster reattachment of neurosensory retina. By the end of the follow-up period, the area of type 1 CNV, and the thickness of the choroid were significantly lower in the main group as compared to the retrospective group. The combined treatment did not cause a single case of complication. Conclusion. The proposed combination of laser exposure followed by IIAI is a safe method for treating complicated forms of CSCRP, which quickens the resorption of subretinal fluid and reduces the number of treatment procedures.","PeriodicalId":36080,"journal":{"name":"Rossiiskii Oftal''mologicheskii Zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rossiiskii Oftal''mologicheskii Zhurnal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21516/2072-0076-2023-16-1-82-89","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: to evaluate the effectiveness of combined treatment of chronic central serous chorioretinopathy (CSCRP) complicated by type 1 choroidal neovascularization (CNV) by subthreshold micropulse laser exposure (SMILE) and intravitreal injection of angiogenesis inhibitors ( IIAI). Material and methods. 37 patients (20 men and 17 women) with monolateral chronic recurrent CSCRP complicated by type 1 CNV, aged 35 to 57 (ave. 43.6 ± 6.7 yrs.) at the moment of first referral, were divided into two groups. The retrospective group included 15 patients (15 eyes) whose first phase of treatment consisted in IIAI (up to 5 injections with an interval of one month). Those who showed no treatment effect were given a SMILE procedure one day before the 6th injection. If neurosensory retinal detachment persisted, the combined treatment (SMILE + IIAI) was repeated monthly until the neurosensory retina could be fully attached, whereupon the patients were transferred to monotherapy with anti-VEGF injections, gradually increasing the interval between the injections. The main group included 22 patients (22 eyes), whose treatment began with a single IIAI. If no neurosensory retinal detachment resorption occurred, the patients received a SMILE procedure one day before the second IIAI injection. The combined treatment was repeated monthly until neurosensory retinal detachment completely resorbed, then the treatment continued with IIAI alone with a gradual increase of intervals between the injections. Results. The number of IIAI in the main group (5 to 8, ave. 6.1 ± 0.8) was significantly lower than in the retrospective group (8 to 10, ave. 8.8 ± 0.77). Best corrected visual acuity increased in both groups, but the main group showed a better central photosensitivity, which is associated with the faster reattachment of neurosensory retina. By the end of the follow-up period, the area of type 1 CNV, and the thickness of the choroid were significantly lower in the main group as compared to the retrospective group. The combined treatment did not cause a single case of complication. Conclusion. The proposed combination of laser exposure followed by IIAI is a safe method for treating complicated forms of CSCRP, which quickens the resorption of subretinal fluid and reduces the number of treatment procedures.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性中枢性浆液性脉络膜视网膜病变合并1型脉络膜新生血管的一种联合治疗方法
目的:评价阈下微脉冲激光照射(SMILE)和玻璃体内注射血管生成抑制剂(IIAI)联合治疗慢性中央浆液性脉络膜视网膜病变(CSCRP)合并1型脉络膜新生血管(CNV)的疗效。材料和方法。37例单侧慢性复发性CSCRP合并1型CNV患者(男性20例,女性17例),首次转诊时年龄35 ~ 57岁(平均43.6±6.7岁),分为两组。回顾性组包括15例患者(15只眼),其第一阶段治疗为IIAI(最多5次注射,间隔1个月)。没有治疗效果的患者在第六次注射前一天接受SMILE治疗。如果神经感觉视网膜脱离持续存在,则每月重复联合治疗(SMILE + IIAI),直到神经感觉视网膜完全附着,然后患者转移到抗vegf注射单药治疗,逐渐增加注射间隔。主要组包括22例患者(22只眼),其治疗开始于单个IIAI。如果没有发生神经感觉视网膜脱离再吸收,患者在第二次注射IIAI前一天接受SMILE手术。联合治疗每月重复一次,直到神经感觉视网膜脱离完全吸收,然后继续单独使用IIAI治疗,注射间隔逐渐增加。结果。主组IIAI数(5 ~ 8例,平均值为6.1±0.8)显著低于回顾性组(8 ~ 10例,平均值为8.8±0.77)。两组患者的最佳矫正视力均有所提高,但主组患者的中枢光敏性较好,这与神经感觉视网膜的快速再植有关。随访结束时,主组1型CNV面积、脉络膜厚度均明显低于回顾性组。联合治疗无一例并发症发生。结论。激光照射联合IIAI是一种治疗复杂CSCRP的安全方法,它可以加速视网膜下液的吸收,减少治疗程序的数量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
107
审稿时长
16 weeks
期刊最新文献
Telemedicine for glaucoma: the state-of-the-art and trends of development Modifying treatment of degenerative retinal diseases. Part 2. Conditioning therapy techniques and the problem of maximizing retinal plasticity Ocular proton therapy: state-of-the-art Methodological aspects of statistical analysis in ophthalmology Keratoprostheses: from the past to the future
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1